

Market Release

2 August 2019

2019 Annual Meeting Results

At AFT Pharmaceuticals Limited's (NZX: AFT / ASX: AFP) shareholder meeting held in Auckland, New Zealand today, shareholders were asked to vote on four ordinary resolutions and one special resolution, which were all supported by the Board. All voting was conducted by a poll.

The ordinary resolutions passed by shareholders were:

1. That the directors are authorised to fix the fees and expenses of Deloitte as auditor for the 2020 financial year.
2. That Dr Hartley Atkinson be re-elected as a director of AFT Pharmaceuticals Limited.
3. That Mr Jon Lamb be re-elected as a director of AFT Pharmaceuticals Limited.
4. That Dr John Douglas Wilson be re-elected as a director of AFT Pharmaceuticals Limited.

The special resolution passed by shareholders was:

5. That the existing constitution of the Company is revoked, and the constitution tabled at the meeting, and referred to in the explanatory notes, is adopted as the constitution of the Company.

Detail of the total number of votes cast in person or by a proxy holder are:

Resolutions	For	Against	Abstain
1. That the directors are authorised to fix the fees and expenses of Deloitte as auditor for the 2020 financial year.	91,099,482 100.00%	0 0.00%	0
2. That Dr Hartley Atkinson be re-elected as a director of AFT Pharmaceuticals Limited	91,099,197 100.00%	0 0.00%	285
3. That Mr Jon Lamb be re-elected as a director of AFT Pharmaceuticals Limited.	90,885,868 100.00%	0 0.00%	213,614
4. That Dr John Douglas Wilson be re-elected as a director of AFT Pharmaceuticals Limited.	91,093,840 100.00%	0 0.00%	5,642
5. That the existing constitution of the Company is revoked, and the constitution tabled at the meeting, and referred to in the explanatory notes, is adopted as the constitution of the Company.	91,091,235 100.00%	4,524 0.00%	3,723

Authority for this announcement	
Name of person authorised to make this announcement	Malcolm Tubby, Chief Financial Officer
Contact person for this announcement	Malcolm Tubby
Contact phone number	+64 9 488 0232
Contact email address	Investor.relations@aftpharm.com
Date of release	02/08/2019